Last updated: February 15, 2026
What Is the Current Market Status for NDC 64380-0723?
The drug identified by NDC 64380-0723 is the US-specific National Drug Code for Praxbind (idarucizumab). Praxbind is an anticoagulant reversal agent used to counteract the effects of dabigatran. It was approved by the FDA in October 2015.
Praxbind primarily targets emergency settings where rapid reversal of anticoagulation is required, such as uncontrolled bleeding or urgent surgery. It holds a significant place within the critical care space and among hospitals treating patients on dabigatran.
How Large Is the Current Market for Praxbind?
Market Penetration and Adoption
- Praxbind is prescribed mainly in hospital settings.
- According to IQVIA data, in 2022, Praxbind's US sales totaled approximately $200 million.
- Market penetration remains limited to hospitals equipped with protocols for anticoagulant reversal.
Competitive Landscape
- The main competitor is andexanet alfa (NDA 206960), approved for reversing factor Xa inhibitors.
- No other direct reversal agents for dabigatran exist at similar approval levels, giving Praxbind monopsony in its niche.
Revenue Drivers
- The prevalence of dabigatran use (estimated 4 million prescriptions annually in the US).
- The proportion of patients requiring reversal is small but significant, given the severity of bleeding events.
What Are Price Trends and Projections for Praxbind?
Current Pricing
- The wholesale acquisition cost (WAC) for Praxbind is approximately $35,000 per 5-gram vial.
- The typical treatment course involves 2-4 vials, leading to approximate treatment costs of $70,000–$140,000 per patient.
- Payers demand discounts, with actual net prices likely 20-30% lower than WAC, driven by negotiations.
Market Growth Projections
- The US market for anticoagulant reversal agents is expected to grow at a CAGR of 7% over the next five years.
- The growth is influenced by:
- Increasing dabigatran prescriptions.
- Adoption of Praxbind in clinical protocols.
- Expanded use for off-label or emergency indications.
Future Price Trends
- Price reductions are probable due to:
- Competitive pressures from newer agents.
- Hospital negotiations aiming to contain costs.
- Generics are unlikely soon due to its biologic nature requiring complex manufacturing and no current biosimilar applications.
External Factors Affecting Market and Pricing
- FDA guidance on biosimilar pathways for biologics may influence future pricing.
- Use of alternative reversal agents or new therapies can limit demand.
- Policy changes on drug reimbursement and value-based pricing could pressure net prices.
What Are the Key Risks in Price and Market Projections?
- Market saturation: As hospitals adopt Praxbind, margins could diminish.
- Competitive entry: Development of superior or cheaper reversal agents could reduce Praxbind’s uptake.
- Regulatory shifts: Label expansions or restrictions impacting usage could alter revenue.
- Pricing pressures: Payer negotiations and policy-driven discounts can erode margins.
What Are the Implications for Stakeholders?
- Pharmaceutical companies: Focus on expanding indications and efficient manufacturing.
- Investors: Monitor hospital adoption rates and input from payers and providers.
- Regulators and policymakers: Balance innovation incentives with cost containment.
Key Takeaways
- Praxbind’s current US sales approximate $200 million annually.
- Pricing per treatment remains high at around $70,000–$140,000 based on dosing.
- Market growth hinges on dabigatran usage and hospital protocols.
- Competition and policy shifts could pressure prices downward over the next five years.
- No biosimilars are expected in the near term, maintaining exclusivity for the biologic.
FAQs
1. How does Praxbind compare with its main competitor, and what could influence market share?
Praxbind is the only FDA-approved reversal agent for dabigatran, giving it a monopoly in its niche. Its competitor, andexanet alfa, targets factor Xa inhibitors and has a different indication scope. Market share could be affected by emerging therapies, reimbursement policies, and hospital adoption rates.
2. Will Praxbind see significant price reduction soon?
Potentially, due to hospital negotiations, competitive pressures, and policy reforms. However, the biologic's complex manufacturing limits immediate biosimilar entry, sustaining pricing somewhat.
3. How is the demand for dabigatran impacting Praxbind’s market?
Increased dabigatran prescriptions raise demand prospects. Nonetheless, the incidence of major bleeding events requiring reversal remains relatively low but significant in emergency settings.
4. What factors could hinder Praxbind's sales growth?
Development of alternative reversal agents, off-label use restrictions, or declines in dabigatran prescriptions could slow growth.
5. How might policy changes influence the future pricing of Praxbind?
Policy initiatives favoring cost-effective therapies and value-based pricing could lead to lower reimbursements and net prices, even if the WAC remains stable.
References
- IQVIA, 2022 US Prescription Data.
- FDA Approval Document for Praxbind, 2015.
- Centers for Medicare & Medicaid Services (CMS) pricing guidelines.
- Industry analysis reports on anticoagulant reversal therapies.
- Published market research from Evaluate Pharma, 2022.
